This article is more than 5 years old. Information may no longer be current.
Top stories in cardiology today
Click Here to Manage Email Alerts
The American College of Cardiology Scientific Session dominated Healio Cardiology’s headlines this week. New studies presented at the meeting touched on such subjects as preeclampsia history and lactation duration, as well as canakinumab demonstration in patient groups. – by Jake Scott
Preeclampsia, lactation duration affect CV risk in women
Two new studies presented at the American College of Cardiology Scientific Session highlight differences in CV risk related to preeclampsia history and lactation duration. Read More.
Therapies for prevention of cardiotoxicity in breast cancer confer mixed results
Two studies of medications for prevention of cardiotoxicity-induced myocardial injury in patients with breast cancer did not meet their primary outcomes, but suggested benefits in certain patients. Read More.
ODYSSEY Outcomes: Alirocumab lowers CV events in acute coronary syndrome population
Reducing LDL to very low levels with the PCSK9 inhibitor alirocumab lowered risk for major adverse CV events and all-cause mortality in patients with acute coronary syndrome on statin therapy, according to results of the ODYSSEY Outcomes trial presented as a late-breaking clinical trial at the American College of Cardiology Scientific Session. Read More.
Statin discontinuation common in high-risk patients
A perceived lack of need is a major reason why patients with elevated CVD risk discontinue statin therapy, according to data presented at the American College of Cardiology Scientific Session. Read More
CANTOS: Canakinumab reduces CV events in CKD, diabetes
Canakinumab demonstrated efficacy in two patient groups with high CV risk and unmet medical need: those with chronic kidney disease and those with diabetes, according to new data from the CANTOS trial presented at the American College of Cardiology Scientific Session. Read More.